Drug Price Trends for NDC 00781-5668

Average Pharmacy Cost for 00781-5668

Drug Name	NDC	Price/Unit ($)	Unit	Date
VORICONAZOLE 200 MG TABLET	00781-5668-31	2.18745	EACH	2026-03-18
VORICONAZOLE 200 MG TABLET	00781-5668-31	2.14054	EACH	2026-02-18
VORICONAZOLE 200 MG TABLET	00781-5668-31	2.00684	EACH	2026-01-21
VORICONAZOLE 200 MG TABLET	00781-5668-31	1.74678	EACH	2025-12-17
VORICONAZOLE 200 MG TABLET	00781-5668-31	1.92932	EACH	2025-11-19
VORICONAZOLE 200 MG TABLET	00781-5668-31	1.92441	EACH	2025-10-22

Best Wholesale Price for NDC 00781-5668

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 00781-5668 (Xeljanz)

Last updated: February 15, 2026

Overview

NDC 00781-5668 corresponds to Xeljanz (tofacitinib), a Janus kinase (JAK) inhibitor approved for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other autoimmune conditions. The drug's patent protections and market exclusivity influence its pricing and competitive positioning.

Market Landscape

Market Size and Growth

• The global rheumatoid arthritis (RA) drug market was valued at approximately $20 billion in 2022 and is projected to grow at a CAGR of 4.5% through 2030 [1].
• Xeljanz holds a significant share, estimated at 12-15% of the RA market in the U.S., due to early adoption and broad US approvals [2].
• The drug also penetrates markets for psoriatic arthritis and ulcerative colitis, expanding its total addressable market (TAM).

Competitive Position

• Competitors include biologic DMARDs like Humira (adalimumab), Enbrel (etanercept), and newer oral agents like Olumiant (baricitinib).
• Biosimilars for biologics could threaten market share; however, small molecule inhibitors like Xeljanz face less biosimilar competition.

Regulatory & Patent Landscape

• Original patent expired in 2021 in the U.S. but some formulations or indications may still be under patent protection or exclusivity in certain jurisdictions.
• Patent cliffs could lead to price erosion and increased generic or biosimilar competition.

Pricing Trends

• List price in the U.S. (per 30-day supply): approximately $3,500 to $4,000 [3].
• Actual net prices, considering discounts, rebates, and insurance negotiations, are typically 20-30% lower than list prices [4].
• Price reductions are anticipated post-patent expiry or with new formulary negotiations.

Price Projections

Time Frame	Price Expectation	Rationale
2023–2024	Stable, slight decline	Market stabilization; rebate pressures; indication expansion due to label updates.
2025–2026	5–10% decline	Patent expiration scenarios; increased biosimilar entry for primary indications.
2027+	15–25% decline	Generic or biosimilar approval in major markets; increased price competition.

Factors Affecting Prices

• Patent expiration timelines or patent challenges.
• Extent of biosimilar and generic supply.
• National reimbursement policies and negotiations.
• Adoption rate changes due to safety concerns or new clinical data.

Impact of Regulatory Changes

• FDA and EMA approval processes influence market entry and pricing strategies.
• Risk of label restrictions, safety warnings, or drug withdrawals can impact marketability and pricing.
• Indication-specific approvals can extend revenue streams and pricing power.

Summary of Key Factors

• The current high list price supports gross revenue but is sensitive to rebate strategies and coverage restrictions.
• Market expansion into new indications could temporarily stabilize or increase prices.
• Market access, including insurance formulary placement, remains critical for revenue realization.
• The eventual biosimilar or generic competition is expected to exert downward pressure, with price declines beginning within 3-5 years after patent expiry.

Key Takeaways

• Xeljanz (NDC 00781-5668) is a key player in the autoimmune therapeutic market with a strong current position.
• Price in the U.S. averages $3,500–$4,000 per month, adjusted by discounts and rebates.
• Market growth depends on indication expansion and competitive dynamics; prices are expected to decline gradually over the next 3–5 years, especially upon patent expiry.
• Regulatory developments, biosimilar approvals, and insurance negotiations will determine future pricing trajectories.

FAQs

1. How does patent expiration influence Xeljanz's pricing?
   Patent expiration allows biosimilars or generics to enter the market, typically leading to a 15–25% price reduction within a few years.

2. What are the primary competitors to Xeljanz?
   Main competitors are biologics like Humira and Enbrel, as well as other small molecule JAK inhibitors like baricitinib (Olumiant).

3. How do rebates affect net prices?
   Rebates and insurance negotiations reduce the effective price paid by payers, often lowering net prices by 20-30% from list prices.

4. What is the outlook for biosimilar competition?
   Biosimilars for biologics targeting RA are already approved in some markets. For Xeljanz, biosimilar competition is less direct but could emerge in treatment areas where it competes with biologics.

5. How might new clinical data impact valuation?
   Positive data on safety, efficacy, or expanded indications can bolster market share and pricing stability. Conversely, safety concerns could restrict use, lowering prices.

Citations

[1] Grand View Research. Rheumatoid Arthritis Market Size, Trends & Growth Forecast. 2022.
[2] IQVIA. US Rheumatoid Arthritis Drug Market Share, 2022.
[3] GoodRx. Xeljanz (tofacitinib) pricing and discounts. 2023.
[4] SSR Health. Pharma rebates and net prices analysis, 2022.